INSYS Therapeutics is a specialty pharmaceutical company with a focus on providing therapeutic solutions helping to improve the lives of patients. Yahoo Finance's Morning Brief. Zynerba Stock Is Marijuana-Adjacent Play Worth a Look. GW Pharma (NASDAQ:GWPH), with its more than $4 billion market cap, is targeting this space and is widely thought of as a leader in cannabinoid writingdesk.pwonally, Insys (NASDAQ:INSY) is. Latest Breaking news and Headlines on Insys Therapeutics, Inc. (INSY) stock from Seeking Alpha. Read the news as it happens!.
(INSY ) Therapeutics, Inc. INSYS
Zynerba has focused on the treatment of seizures in particular. Within that particular space, it faces cannabinoid-based competition on several fronts. So, should Zynerba's ZYN be a clinical success, it won't necessarily be the first or best therapy that reaches the market. What happened on Jan. There doesn't appear to be much in the way of hard news, but the company did give a high-profile presentation and it appears this set investor enthusiasm in motion.
Zynerba also expects to release results for its Phase 2 trial for developmental and epileptic encephalopathies in the latter half of To add to that, Zynerba remains in reasonably strong financial position.
Given its current burn rate, that should give Zynerba funds to continue its current research through the second half of While Zynerba will have to raise more funds at some point, it still has plenty of time to deliver its crucial trial results later in before going back to the market for more money.
CGC are soaring almost every day. Zynerba itself hadn't participated in this enthusiasm, at least not until recently. However, that may be changing.
Recently, famous TV host Jim Cramer talked up so-called "marijuana-adjacent" biotech firms as stocks with big potential in They are drug companies focused on developing artificial cannabinoids that mimic what cannabis does to your body […] As we get more and more data showing the efficacy of medicinal marijuana, I think more investors will embrace actual medicines that do the same thing as marijuana, but they do it more reliably.
Zynerba Stock VerdictI rarely invest in clinical stage biotech companies. It's a difficult industry; far more companies fail than succeed. Be careful with these sorts of stocks and don't invest more than you can afford to lose. That said, Zynerba has an interesting drug candidate, and is certainly positioned in a hot sector of the market.
With plenty of cash to make it into mid, and key data coming before then, ZYNE stock has plenty of speculative value for active traders. One upcoming catalyst to watch out for. With ZYNE stock remaining volatile in recent days, any further data releases or business updates in this presentation could cause a big move in Zynerba shares. At the time of this writing, Ian Bezek held no positions in any of the aforementioned securities.
You can reach him on Twitter at irbezek. Search Now you can search stock related news and private companies such as Airbnb. The plume disperses a small volume of liquid across the surface area of the sublingual mucosa and facilitates rapid absorption by the body. The Company's lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.
Dronabinol is a synthetic form of deltatetrahydrocannabinol THC. THC is an orally active cannabinoid. The Company is developing a Cannabidiol Oral Solution, a synthetic cannabidiol, for childhood catastrophic epilepsy syndromes focusing on Dravet syndrome, Lennox-Gastaut syndrome and Infantile Spasms. The Company is conducting approximately two studies in epilepsy: The Company's other product candidates include other dronabinol line extensions and sublingual spray product candidates.
Breakingviews Home Breakingviews Video. Subsys Sublingual Fentanyl Spray The Company's product, Subsys, delivers a liquid fentanyl formulation in approximately , , , , , 1, and 1, micrograms mcg dosages.
Better Patient Care Through Innovation
PHOENIX, Jan. 09, (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. ( NASDAQ: INSY), a leader in the development, manufacture and. Insys Therapeutics, Inc., incorporated on June 15, , is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes . Insys Therapeutics Inc. stock price, stock quotes and financial overviews from MarketWatch.